Compositions and methods for treating lung diseases
By using compound 1 and compound 2, the treatment problems of idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis were solved, and the symptoms and quality of life of lung diseases were significantly improved, and effective pulmonary fibrosis and inflammation were achieved. control.
Patent Information
- Application Number
- CN202110872658.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2020-07-31
- Filing Date
- 2021-07-30
- Publication Date
- 2024-11-19
- Estimated Expiration
- 2041-07-30
AI Technical Summary
The prior art is difficult to effectively treat or prevent idiopathic pulmonary fibrosis (IPF) and radiation-induced pulmonary fibrosis (RIPF). These two lung diseases lead to irreversible damage to the lungs and interruption of gas exchange, which seriously affects the quality of life of patients. .
Using compound 1 and compound 2 or its pharmaceutically acceptable salts, administered by oral, intravenous, tracheal infusion, etc., significantly improve the symptoms of lung disease, reduce pulmonary fibrosis and inflammation scores, reduce collagen deposition and senescent cells. quantity, increase survival rate.
Compounds 1 and 2 significantly improved survival and lung function in mouse models of idiopathic pulmonary fibrosis and radiation-induced pulmonary fibrosis, reduced pulmonary fibrosis and inflammation scores, reduced collagen deposition and senescent cell count, and increased The quality of life of the patients.
Smart Images

Figure BDA0003189683680000031 
Figure BDA0003189683680000041 
Figure FDA0005086037700000011
Abstract
Description
Background Art
[0001] Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive lung disease characterized by progressive lung scarring and histologic findings of usual interstitial pneumonia (UIP). It is associated with worsening cough and dyspnea and decreased quality of life. IPF affects approximately 3 million people worldwide, with incidence increasing significantly with age (Nat. Rev. Dis. Primers 3;17074 (2017)).
[0002] Radiation-induced pulmonary fibrosis (RIPF) is a common complication of lung cancer and breast cancer patients who receive thoracic radiotherapy. The average incidence of RIPF after radiotherapy is 16%-28%. RIPF comprises a heterogeneous group of lung diseases characterized by progressive and irreversible destruction of the lungs and disruption of gas exchange (Translational Oncology 12; 162–169 (2019)). Therefore, new methods for treating or preventing lung diseases such as idiopathic pulmonary fibrosis (IPF) or radiation-induced pulmonary fibrosis (RIPF) are needed. The present invention addresses this need.
[0003] Overview
[0004] In some aspects, the present invention provides a method for treating or preventing a lung disease in a subject, comprising administering to the subject a pharmaceutically effective amount of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0005] In some aspects, the present invention provides a method for using Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof to treat or prevent a lung disease in a subject.
[0006] In some aspects, the present invention provides a use of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or preventing a lung disease in a subject.
[0007] In some aspects, the present invention provides a pharmaceutical composition for treating or preventing a lung disease, comprising Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0008] In some aspects, the present invention provides a pharmaceutical kit for treating or preventing a lung disease, comprising Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0009] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. In the specification, the singular also includes the plural, unless the context clearly states otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. All publications, patent applications, patents and other references mentioned herein are incorporated by reference. The references cited herein are not considered to be prior art of the claimed invention. In the event of a conflict, this specification (including definitions) shall prevail. In addition, materials, methods and embodiments are illustrative only and not restrictive. In the event of a conflict between the chemical structure and the name of the compound disclosed herein, the chemical structure shall prevail.
[0010] Other features and advantages of the invention will be apparent from the following detailed description, and from the claims. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1A and 1B is a set of graphs showing that Compound 1 and Compound 2 significantly improved body weight loss and survival rate in mice with idiopathic pulmonary fibrosis.
[0012] Figure 2A and 2B is a set of graphs showing that Compound 1 and Compound 2 significantly improved lung fibrosis and inflammation scores in mice with idiopathic pulmonary fibrosis.
[0013] Figure 3 Compound 1 was shown to significantly reduce collagen deposition in the lungs of mice with idiopathic pulmonary fibrosis.
[0014] Figure 4 Compounds 1 and 2 significantly reduced the number of SA-β-galactosidase-positive cells in the lungs of mice with idiopathic pulmonary fibrosis
[0015] Figure 5 The results showed that compound 1 and compound 2 significantly reduced the mRNA level of p16 gene in the lungs of mice with idiopathic pulmonary fibrosis.
[0016] Fig. 6A and 6B Bleomycin challenge significantly increased the mRNA level of the BCL-xL gene in the mouse lung.
[0017] Figures 7A-7F Compounds 1 and 2 significantly reduced the mRNA levels of SASP-related genes in the lungs of mice with idiopathic pulmonary fibrosis
[0018] Fig. 8A and 8Bis a set of graphs showing that the expression level of BCL-xL protein in the lungs of mice challenged with bleomycin was significantly increased compared to untreated mice.
[0019] Fig. 9 It was shown that compounds 1 and 2 significantly improved the survival rate of mice with radiation-induced pulmonary fibrosis.
[0020] Fig.10 Compounds 1 and 2 were shown to significantly reduce lung size in mice with radiation-induced pulmonary fibrosis
[0021] Fig.11 Compound 2 significantly reduced the number of senescent cells in the lungs of mice with radiation-induced pulmonary fibrosis Detailed description
[0022] It should be understood that the term "Compound 1" as used herein refers to a compound having the following structure:
[0023]
[0024] Compound 1 can be named by IUPAC as (3R)-1-(3-(4-(4-(3-(2-(4-chlorophenyl))-1-isopropyl-4-methanesulfonyl-5-methyl-1H-pyrrol-3-yl)-5-fluorophenyl)piperazin-1-yl)-phenylaminosulfonyl)-2-trifluoromethylsulfonyl-anilino)-4-phenylthio-butyl)-piperidine-4-carboxylic acid 3-phosphonopropyl ester.
[0025] It should be understood that the term "Compound 2" as used herein refers to a compound having the following structure:
[0026]
[0027] Compound 2 can be named by IUPAC as (R)-1-(3-((4-(N-(4-(4-(3-(2-(4-chlorophenyl))-1-isopropyl-5-methyl-4-(methylsulfonyl)-1H-pyrrol-3-yl)-5-fluorophenyl)-piperazin-1-yl)phenyl)sulfamoyl)-2-((trifluoromethyl)sulfonyl)phenyl)amino)-4-(phenylthio)-butyl)piperidine-4-carboxylic acid.
[0028] Methods and uses of the present invention
[0029] In some aspects, the present invention provides a method for treating or preventing a lung disease in a subject, comprising administering to the subject a pharmaceutically effective amount of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0030] In some aspects, the present invention provides a method for treating or preventing a lung disease in a subject, comprising administering to the subject a pharmaceutically effective amount of Compound 1 or a pharmaceutically acceptable salt thereof.
[0031] In some aspects, the present invention provides a method of treating or preventing a lung disease in a subject, comprising administering to the subject a therapeutically effective amount of Compound 2 or a pharmaceutically acceptable salt thereof.
[0032] In some aspects, the present invention provides Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof for use in treating or preventing a lung disease in a subject.
[0033] In some aspects, the present invention provides Compound 1 or a pharmaceutically acceptable salt thereof for use in treating or preventing a lung disease in a subject.
[0034] In some aspects, the present invention provides Compound 2 or a pharmaceutically acceptable salt thereof for use in treating or preventing a lung disease in a subject.
[0035] In some aspects, the present invention provides a use of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or preventing a lung disease in a subject.
[0036] In some aspects, the present invention provides a use of Compound 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing a lung disease in a subject.
[0037] In some aspects, the present disclosure provides the use of Compound 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing a lung disease in a subject.
[0038] Exemplary embodiments of methods and uses
[0039] In some aspects, the present invention provides a method for treating or preventing idiopathic pulmonary fibrosis (IPF) in a subject, comprising administering to the subject a pharmaceutically effective amount of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0040] In some aspects, the present invention provides a method of treating or preventing idiopathic pulmonary fibrosis (IPF) in a subject, comprising administering to the subject a pharmaceutically effective amount of Compound 1 or a pharmaceutically acceptable salt thereof.
[0041] In some aspects, the present invention provides a method of treating or preventing idiopathic pulmonary fibrosis (IPF) in a subject, comprising administering to the subject a pharmaceutically effective amount of Compound 2 or a pharmaceutically acceptable salt thereof.
[0042] In some aspects, the present invention provides Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof for use in treating or preventing idiopathic pulmonary fibrosis (IPF) in a subject.
[0043] In some aspects, the present invention provides Compound 1 or a pharmaceutically acceptable salt thereof for use in treating or preventing idiopathic pulmonary fibrosis (IPF) in a subject.
[0044] In some aspects, the present invention provides Compound 2 or a pharmaceutically acceptable salt thereof for use in treating or preventing idiopathic pulmonary fibrosis (IPF) in a subject.
[0045] In some aspects, the present invention provides a use of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or preventing idiopathic pulmonary fibrosis (IPF) in a subject.
[0046] In some aspects, the present invention provides a use of Compound 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing idiopathic pulmonary fibrosis (IPF) in a subject.
[0047] In some aspects, the present invention provides the use of Compound 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing idiopathic pulmonary fibrosis (IPF) in a subject.
[0048] In some aspects, the present invention provides a method of treating or preventing radiation-induced pulmonary fibrosis (RIPF) in a subject, comprising administering to the subject a pharmaceutically effective amount of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0049] In some aspects, the present invention provides a method of treating or preventing radiation-induced pulmonary fibrosis (RIPF) in a subject, comprising administering to the subject a pharmaceutically effective amount of Compound 1 or a pharmaceutically acceptable salt thereof.
[0050] In some aspects, the present invention provides a method of treating or preventing radiation-induced pulmonary fibrosis (RIPF) in a subject, comprising administering to the subject a pharmaceutically effective amount of Compound 2 or a pharmaceutically acceptable salt thereof.
[0051] In some aspects, the present invention provides Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof for use in treating or preventing radiation-induced pulmonary fibrosis (RIPF) in a subject.
[0052] In some aspects, the present disclosure provides Compound 1 or a pharmaceutically acceptable salt thereof for use in treating or preventing radiation-induced pulmonary fibrosis (RIPF) in a subject.
[0053] In some aspects, the present disclosure provides Compound 2 or a pharmaceutically acceptable salt thereof for use in treating or preventing radiation-induced pulmonary fibrosis (RIPF) in a subject.
[0054] In some aspects, the present invention provides a use of Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof, in the preparation of a medicament for treating or preventing radiation-induced pulmonary fibrosis (RIPF) in a subject.
[0055] In some aspects, the present invention provides a use of Compound 1 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing radiation-induced pulmonary fibrosis (RIPF) in a subject.
[0056] In some aspects, the present disclosure provides the use of Compound 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing radiation-induced pulmonary fibrosis (RIPF) in a subject.
[0057] Suitable subjects and diseases
[0058] In some embodiments, the subject is a mammal.
[0059] In some embodiments, the subject is a mouse.
[0060] In some embodiments, the subject is a human.
[0061] In some embodiments, the lung disease is an interstitial lung disease.
[0062] In some embodiments, the lung disease is pulmonary fibrosis.
[0063] In some embodiments, the lung disease is idiopathic pulmonary fibrosis (IPF).
[0064] In some embodiments, the lung disease is a radiation-induced lung disease.
[0065] In some embodiments, the lung disease is radiation-induced interstitial lung disease.
[0066] In some embodiments, the lung disease is radiation-induced pulmonary fibrosis (RIPF).
[0067] Administration of Compound 1
[0068] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered by enteral administration.
[0069] In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered orally.
[0070] In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered parenterally.
[0071] In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered intravenously.
[0072] In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered by intratracheal instillation.
[0073] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered once a day.
[0074] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered twice daily.
[0075] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered three or more times per day.
[0076] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered once a week.
[0077] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered twice a week.
[0078] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered three or more times per week.
[0079] In some embodiments, there are one or more drug holidays during administration of Compound 1 or a pharmaceutically acceptable salt thereof.
[0080] In some embodiments, Compound 1 or a pharmaceutically acceptable salt thereof is administered without a drug holiday.
[0081] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered for about 1 week, about 2 weeks, or about 3 weeks.
[0082] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered for about 3 weeks.
[0083] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered twice a week (eg, on day 1 and day 4) for about three weeks.
[0084] In some embodiments, Compound 1, or a pharmaceutically acceptable salt thereof, is administered once daily for about three weeks.
[0085] Administration of Compound 2
[0086] In some embodiments, Compound 2, or a pharmaceutically acceptable salt thereof, is administered by enteral administration.
[0087] In some embodiments, Compound 2 or a pharmaceutically acceptable salt thereof is administered orally.
[0088] In some embodiments, Compound 2 or a pharmaceutically acceptable salt thereof is administered parenterally.
[0089] In some embodiments, Compound 2 or a pharmaceutically acceptable salt thereof is administered intravenously.
[0090] In some embodiments, Compound 2 or a pharmaceutically acceptable salt thereof is administered by intratracheal instillation.
[0091] In some embodiments, Compound 2, or a pharmaceutically acceptable salt thereof, is administered once a day.
[0092] In some embodiments, Compound 2, or a pharmaceutically acceptable salt thereof, is administered twice daily.
[0093] In some embodiments, Compound 2, or a pharmaceutically acceptable salt thereof, is administered three or more times per day.
[0094] In some embodiments, Compound 2, or a pharmaceutically acceptable salt thereof, is administered once a week.
[0095] In some embodiments, Compound 2, or a pharmaceutically acceptable salt thereof, is administered twice a week.
[0096] In some embodiments, Compound 2 or a pharmaceutically acceptable salt thereof is administered three or more times per week.
[0097] In some embodiments, there are one or more drug holidays during administration of Compound 2 or a pharmaceutically acceptable salt thereof.
[0098] In some embodiments, Compound 2 or a pharmaceutically acceptable salt thereof is administered without a drug holiday.
[0099] In some embodiments, Compound 2, or a pharmaceutically acceptable salt thereof, is administered for about 1 week, about 2 weeks, or about 3 weeks.
[0100] In some embodiments, Compound 2, or a pharmaceutically acceptable salt thereof, is administered for about 3 weeks.
[0101] In some embodiments, Compound 2 or a pharmaceutically acceptable salt thereof is administered twice a week (e.g., on Day 1 and Day 4) for about three weeks.
[0102] In some embodiments, Compound 2, or a pharmaceutically acceptable salt thereof, is administered once daily for about three weeks.
[0103] Pharmaceutical compositions and kits
[0104] In some aspects, the present invention provides a pharmaceutical composition for treating or preventing a lung disease, comprising Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0105] In some aspects, the present invention provides a pharmaceutical composition for treating or preventing idiopathic pulmonary fibrosis (IPF), comprising Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0106] In some aspects, the present invention provides a pharmaceutical composition for treating or preventing radiation-induced pulmonary fibrosis (RIPF), comprising Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0107] In some embodiments, the pharmaceutical composition comprises Compound 1 or a pharmaceutically acceptable salt thereof.
[0108] In some embodiments, the pharmaceutical composition comprises Compound 2 or a pharmaceutically acceptable salt thereof.
[0109] In some aspects, the present invention provides a pharmaceutical kit for treating or preventing a lung disease, comprising Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0110] In some aspects, the present invention provides a pharmaceutical kit for treating or preventing idiopathic pulmonary fibrosis (IPF), comprising Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0111] In some aspects, the present invention provides a pharmaceutical kit for treating or preventing radiation-induced pulmonary fibrosis (RIPF), comprising Compound 1, Compound 2, or a pharmaceutically acceptable salt thereof.
[0112] In some embodiments, the pharmaceutical kit comprises Compound 1 or a pharmaceutically acceptable salt thereof.
[0113] In some embodiments, the pharmaceutical kit comprises Compound 2 or a pharmaceutically acceptable salt thereof.
[0114] The pharmaceutical composition containing the active compound of the disclosure of the present invention can be manufactured in a known manner, for example, by conventional mixing, dissolving, granulating, making dragees, grinding, emulsifying, encapsulating, embedding or lyophilizing processes. One or more pharmaceutically acceptable carriers can be used to prepare the pharmaceutical composition in a conventional manner, and the carrier includes excipients and / or adjuvants that help the active compound to be processed into pharmaceutically acceptable preparations. Of course, suitable preparations depend on the selected route of administration.
[0115] Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL TM(BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be fluid to the extent that it is easy to inject. It must be stable under manufacturing and storage conditions and must be able to prevent contamination by microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium comprising, for example, water, ethanol, polyols (such as glycerol, propylene glycol and liquid polyethylene glycol, etc.) and suitable mixtures thereof. For example, appropriate fluidity can be maintained by using a coating such as lecithin, by maintaining the desired particle size in the case of dispersion, and by using a surfactant. The action of microorganisms can be prevented by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, etc. In many cases, it is preferred to include isotonic agents in the composition, such as sugars, polyols such as mannitol and sorbitol, and sodium chloride. The extended absorption of the injectable composition can be achieved by including an agent that delays absorption in the composition, such as aluminum monostearate and gelatin.
[0116] Sterile injectable solutions can be prepared by incorporating the required amount of the active compound in an appropriate solvent, combining one or more of the above ingredients as required, and then filtering to sterilize. Generally, dispersions are prepared by incorporating the active compound into a sterile carrier that contains a basic dispersion medium and the required other ingredients from those enumerated above. For the preparation of sterile powders for injectable solutions, the preparation methods are vacuum drying and freeze drying of a powder of the active ingredient plus any other desired ingredients from a previously sterile-filtered solution thereof.
[0117] Oral compositions typically include an inert diluent or an edible pharmaceutically acceptable carrier. They can be encapsulated in gelatin capsules or compressed into tablets. For oral therapeutic administration, the active compound can be mixed with an excipient and used in the form of tablets, lozenges or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is orally administered and gargled and coughed or swallowed. Pharmaceutically compatible binders and / or adjuvant materials can be included as part of the composition. Tablets, pills, capsules, lozenges, etc. may contain any of the following ingredients or compounds of similar nature: binders such as microcrystalline cellulose, tragacanth or gelatin; excipients such as starch or lactose, disintegrants such as alginic acid, primary gel, corn starch; lubricants such as magnesium stearate or steroids; glidants such as colloidal silicon dioxide; sweeteners such as sucrose or saccharin; or flavorings such as mint, methyl salicylate or orange flavoring.
[0118] For administration by inhalation, the compounds are delivered in the form of an aerosol spray from a pressured container or dispenser which contains a suitable propellant, e.g., a gas such as carbon dioxide, or a nebulizer.
[0119] Systemic administration can also be carried out through mucosal or transdermal means. For transmucosal or transdermal administration, penetrants suitable for penetration barriers are used in the formulation. Such penetrants are generally known in the art and include, for example, detergents, bile salts and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be accomplished by using nasal sprays or suppositories. For transdermal administration, the active compound is formulated into an ointment, salves, gel or cream well known in the art.
[0120] The active compound can be prepared with a pharmaceutically acceptable carrier that will protect the compound from rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable biocompatible polymers such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid can be used. The method for preparing such a preparation is obvious to those skilled in the art. These materials can also be purchased from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells, with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in patent US4,522,811.
[0121] It is particularly advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms disclosed herein is dictated by and directly dependent on the unique characteristics of the active compound and the specific therapeutic effect to be achieved.
[0122] In therapeutic applications, the dosage of the pharmaceutical composition used according to the disclosure of the present invention depends on the reagent, age, weight and clinical condition of the patient, the experience and judgment of the clinician or practitioner who gives the treatment, and other factors that affect the selected dosage. Generally, the dosage should be sufficient to cause the symptoms of the disease to slow down, preferably the symptoms disappear, and also preferably the disease disappears completely.
[0123] It will be understood that the pharmaceutical compositions may be included in a container, pack, or dispenser together with instructions for administration.
[0124] definition
[0125] As used herein, the term "about" refers to a range that encompasses any normal fluctuations understood by a person of ordinary skill in the relevant art. In some embodiments, the term "about" refers to a range that falls within 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less in either direction (greater or less than) the reference value, unless otherwise stated or obvious from the context (unless such number exceeds 100% of the possible value). 13338693199
[0126] As used herein, the term "pharmaceutically acceptable salt" refers to a derivative of the compounds disclosed herein, wherein the parent compound is modified by preparing its acid or base salt. Examples of pharmaceutically acceptable salts include, but are not limited to, inorganic or organic acid salts of basic residues such as amines, alkali metal or organic salts of acidic residues such as carboxylic acids, and the like. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, those derived from 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptanoic acid, gluconic acid, glutamic acid, glycolic acid, ethylene glycol aniline, hexylresorcinol, carbamic acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthoic acid, isoethanesulfonic acid, lactic acid, lactobionic acid, laurylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, naphthoic acid, nitric acid, oxalic acid, benzoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, acetic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tannin, tartaric acid, toluenesulfonic acid, and common amino acids such as glycine, alanine, phenylalanine, arginine, and the like. Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-dec-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, muconic acid, and the like. The present invention also includes salts formed when the acid proton present in the parent compound is replaced by a metal ion, such as an alkali metal ion, an alkaline earth metal ion, or an aluminum ion; or coordinated with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. In salt form, it is understood that the ratio of the compound to the cation or anion of the salt can be 1:1, or any ratio other than 1:1, such as 3:1, 2:1, 1:2, or 1:3. It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same salt.
[0127] It should be understood that the compounds described herein include the compounds themselves, as well as their pharmaceutically acceptable salts and their solvates, if applicable. For example, pharmaceutically acceptable salts can be formed between pharmaceutically acceptable anions and positively charged groups (e.g., amino groups) on substituted benzene compounds. Suitable anions include chlorides, bromides, iodides, sulfates, bisulfates, sulfamates, nitrates, phosphates, citrates, methanesulfonates, trifluoroacetates, glutamates, glucuronates, glutarates, malates, maleates, succinates, fumarates, tartrates, toluenesulfonates, salicylates, lactates, naphthoates, phthalates, and acetates (e.g., trifluoroacetates).
[0128] As used herein, the term "pharmaceutically acceptable anion" refers to an anion suitable for forming a pharmaceutically acceptable salt. Similarly, salts can also be formed between cations and negatively charged groups (e.g., carboxylates) on substituted benzene compounds. Suitable cations include sodium ions, potassium ions, magnesium ions, calcium ions, and ammonium cations such as tetramethylammonium ions. Substituted benzene compounds also include those salts containing quaternary nitrogen atoms.
[0129] It should be understood that the compounds disclosed in the present invention, such as salts of compounds, can exist in hydrated or unhydrated (anhydrous) form or as solvates with other solvent molecules. Non-limiting examples of hydrates include monohydrates and dihydrates. Non-limiting examples of solvates include ethanol solvates and acetone solvates.
[0130] As used herein, the expressions "one or more of A, B or C", "one or more of A, B or C", "one or more of A, B and C", "one or more A, B and C", "selected from A, B and C", "selected from A, B and C", etc. are used interchangeably and refer to a group selected from A, B and / or C, i.e., one or more A, one or more B, one or more C, or any combination thereof, unless otherwise specified.
[0131] It should be understood that throughout the specification, where a composition is described as having, including or comprising a particular component, it is contemplated that the composition is also substantially composed of or consists of said component. Similarly, where a method or process is described as having, including or comprising a particular process step, the process is also substantially composed of or consists of said process step. In addition, it should be understood that the order of steps or the order in which certain actions are performed is insignificant as long as the present invention remains operable. In addition, two or more steps or actions may be performed simultaneously.
[0132] It should be understood that the compounds disclosed herein can be prepared in a variety of ways using standard synthetic methods and procedures known to those skilled in the art, using commercially available starting materials, compounds known in the literature, or from readily prepared intermediates, or in light of the teachings herein, which will be apparent to those skilled in the art. Standard synthetic methods and procedures for preparing organic molecules and functional group transformations and manipulations can be obtained from the relevant scientific literature or standard textbooks in the field. Although not limited to any one or more sources, classic textbooks such as Smith, MB, March, J., March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5 th edition, John Wiley & Sons: New York, 2001; Greene, TW, Wuts, PGM, Protective Groups in Organic Synthesis, 3 rd edition, John Wiley & Sons: New York, 1999; R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Organic Synthesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic Synthesis, John Wiley and Sons (1995), are useful and recognized reference textbooks on organic synthesis known to those skilled in the art.
[0133] As used herein, the term "subject" is interchangeable with the term "subject in need thereof," both of which refer to a subject suffering from a disease or having an increased risk of developing the disease. "Subject" includes mammals. The mammal can be, for example, a human or a suitable non-human mammal, such as a primate, mouse, rat, dog, cat, cow, horse, goat, camel, sheep, or pig. The subject can also be a bird or poultry. In some embodiments, the mammal is a human.
[0134] As used herein, the term "treating" or "treatment" describes the management and care of a patient for the purpose of combating a disease, disorder, or condition, and includes the administration of a compound disclosed herein, or a pharmaceutically acceptable salt, polymorph, or solvate thereof, to alleviate the symptoms or complications of a disease, disorder, or condition, or to eliminate a disease, disorder, or disease disorder. The term "treatment" may also include treatment of in vitro cells or animal models.
[0135] It will be appreciated that the compounds disclosed herein, or pharmaceutically acceptable salts, polymorphs or solvates thereof, may be or may also be used to prevent related diseases, conditions or disorders, or to identify suitable candidates for such purposes.
[0136] As used herein, the terms "preventing," "prevent," or "preventing" describe the reduction or elimination of the onset of symptoms or complications of such disease, condition, or disorder.
[0137] As used herein, the term "pharmaceutical composition" is a preparation containing the compounds of the present invention, which is in a form suitable for administration to a subject. In one embodiment, the pharmaceutical composition is in bulk or in unit dosage form. The unit dosage form is any of a variety of forms, including, for example, a single pump or vial on a capsule, an intravenous bag, a tablet, an aerosol inhaler. The amount of active ingredient (e.g., a preparation of a disclosed compound or its salt, hydrate, solvate, or isomer) in a unit dose of the composition is an effective amount and varies according to the specific treatment involved. It will be appreciated by those skilled in the art that it is sometimes necessary to make routine changes to the dosage according to the age and condition of the patient. The dosage will also depend on the route of administration. A variety of routes are contemplated, including oral, pulmonary, rectal, parenteral, transdermal, subcutaneous, intravenous, intramuscular, intraperitoneal, inhalation, oral, sublingual, intrapleural, intrathecal, intranasal, etc. The dosage forms for topical or transdermal administration of the compounds disclosed in the present invention include powders, sprays, ointments, pastes, creams, lotions, gels, solutions, patches, and inhalants. In one embodiment, the active compound is mixed under sterile conditions with a pharmaceutically acceptable carrier and any preservatives, buffers, or propellants that are required.
[0138] As used herein, the term "pharmaceutically acceptable" refers to those compounds, anions, cations, materials, compositions, carriers and / or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, other problems or complications, commensurate with a reasonable benefit / risk ratio.
[0139] As used herein, the term "pharmaceutically acceptable excipient" refers to an excipient that can be used to prepare a pharmaceutical composition that is generally safe, non-toxic, and has no adverse effects biologically or otherwise, including excipients that can be used for veterinary and human use. "Pharmaceutically acceptable excipient" used in the specification and claims includes one and more than one such excipient.
[0140] As used herein, the term "pharmaceutically effective amount" refers to the amount of a medicament that is used to treat, improve or prevent a determined disease or condition, or that exhibits a detectable therapeutic or inhibitory effect. The effect can be detected by any assay method known in the art. The precise effective amount for a subject will depend on the subject's weight, size and health, the nature and extent of the condition, and the therapeutic agent or combination of therapeutic agents selected for administration. The pharmaceutically effective amount for a given situation can be determined by routine experimentation within the skill and judgment of the clinician.
[0141] It should be understood that for compounds disclosed herein that are capable of further forming salts, all such forms are also included within the scope of the claimed disclosure.
[0142] As used herein, the term "pharmaceutically acceptable salt" refers to a derivative of a compound of the present disclosure in which the parent compound is modified by preparing an acid or base salt thereof. In some embodiments, a pharmaceutically acceptable salt of a compound is also a prodrug of the compound. Examples of pharmaceutically acceptable salts include, but are not limited to, basic residues such as inorganic or organic acid salts of amines, acidic residues such as alkali metal or organic salts of carboxylic acids, and the like. Pharmaceutically acceptable salts include conventional non-toxic salts or quaternary ammonium salts of the parent compound formed, for example, by non-toxic inorganic or organic acids. For example, such conventional non-toxic salts include, but are not limited to, those derived from 2-acetoxybenzoic acid, 2-hydroxyethanesulfonic acid, acetic acid, ascorbic acid, benzenesulfonic acid, benzoic acid, bicarbonate, carbonic acid, citric acid, edetic acid, ethanedisulfonic acid, 1,2-ethanesulfonic acid, fumaric acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, ethylene glycol aniline, hexylresorcinol, carbamic acid, hydrobromic acid, hydrochloric acid, hydroiodic acid, hydroxymaleic acid, hydroxynaphthoic acid, isoethanesulfonic acid, lactic acid, lactobionic acid, laurylsulfonic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, naphthoic acid, nitric acid, oxalic acid, benzoic acid, pantothenic acid, phenylacetic acid, phosphoric acid, polygalacturonic acid, propionic acid, salicylic acid, stearic acid, acetic acid, succinic acid, sulfamic acid, sulfanilic acid, sulfuric acid, tannin, tartaric acid, toluenesulfonic acid, and common amino acids such as glycine, alanine, phenylalanine, arginine, and the like.
[0143] Other examples of pharmaceutically acceptable salts include hexanoic acid, cyclopentanepropionic acid, pyruvic acid, malonic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, 4-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid, 4-toluenesulfonic acid, camphorsulfonic acid, 4-methylbicyclo-[2.2.2]-dec-2-ene-1-carboxylic acid, 3-phenylpropionic acid, trimethylacetic acid, tert-butylacetic acid, muconic acid, and the like. The present invention also includes salts formed when the acid proton present in the parent compound is replaced by a metal ion, such as an alkali metal ion, an alkaline earth metal ion, or an aluminum ion; or coordinated with an organic base such as ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. In salt form, it is understood that the ratio of the compound to the cation or anion of the salt can be 1:1, or any ratio other than 1:1, such as 3:1, 2:1, 1:2, or 1:3.
[0144] It should be understood that all references to pharmaceutically acceptable salts include solvent addition forms (solvates) or crystal forms (polymorphs) as defined herein, of the same salt.
[0145] As used herein, the term "prodrug" refers to any agent that is converted in whole or in part to a targeted compound when administered to a mammal. In some embodiments, a prodrug of a compound is also a pharmaceutically acceptable salt of the compound.
[0146] It should be understood that the compounds disclosed in the present invention can also be prepared as esters, such as pharmaceutically acceptable esters. For example, the carboxylic acid functional group in the compound can be converted into its corresponding ester, such as methyl, ethyl or other esters. In addition, the alcohol group in the compound can be converted into its corresponding ester, such as acetate, propionate or other esters.
[0147] The compound or its pharmaceutically acceptable salt is administered orally, nasally, transdermally, pulmonary, by inhalation, buccal, sublingual, intraperitoneal, subcutaneous, intramuscular, intravenous, rectal, intrapleural, intrathecal and parenteral. In one embodiment, the compound is administered orally. Those skilled in the art will recognize the advantages of a particular route of administration.
[0148] The dosage regimen for using the compound is selected based on a variety of factors, including the type, species, age, weight, sex and medical condition of the patient, the severity of the condition to be treated, the route of administration, the patient's renal and liver function, and the specific compound or salt thereof used. An ordinary skilled physician or veterinarian can readily determine and prescribe the effective amount of the drug required to prevent, counter or arrest the progress of the condition.
[0149] The formulation and administration techniques of the compounds disclosed in the present invention can be found in Remington: the Science and Practice of Pharmacy, 19 thedition, Mack Publishing Co., Easton, PA (1995). In one embodiment, the compounds described herein and pharmaceutically acceptable salts thereof are used in combination with a pharmaceutically acceptable carrier or diluent in a pharmaceutical formulation. Suitable pharmaceutically acceptable carriers include inert solid fillers or diluents and sterile aqueous or organic solutions. The compound will be present in such pharmaceutical compositions in an amount sufficient to provide the desired dosage within the range described herein.
[0150] Unless otherwise indicated, all percentages and ratios used herein are by weight. Other features and advantages of the present disclosure are apparent from the various examples. The examples provided illustrate the various components and methods that can be used to practice the present disclosure. The examples do not limit the scope of the claims. Based on the present disclosure, a skilled person can identify and adopt other components and methods that can be used to practice the present disclosure.
[0151] All publications and patent documents cited herein are incorporated herein by reference, similar to each publication or document specifically and individually incorporated herein by reference. Citation of publications and patent documents does not mean that they are related prior art, nor does it constitute any admission of their content or date. The present invention has now been described by way of written description, and those skilled in the art will recognize that the present invention can be implemented in various embodiments, and the foregoing description and the following examples are intended to illustrate rather than limit the claims. Example
[0152] Example 1. Study of Compound 1 and Compound 2 in an idiopathic pulmonary fibrosis mouse model.
[0153] Mouse model of idiopathic pulmonary fibrosis. All animal experiments were obtained from Shanghai Ruizhi Chemical Research Co., Ltd. (Shanghai, China). Male C57BL / 6 mice (6-8 weeks old, 18-20 g) were randomly divided into the following 4 groups: (1) untreated group, (2) model + solvent group, (3) compound 1 group, and (4) compound 2 group. The mice in the naive group were instilled with 50 mL of 0.9% saline into the trachea and were not treated until they were killed. The mice in the other three groups were instilled with 50 μL of bleomycin into the trachea at a dose of 1 unit / kg, and then the solvent (model-solvent group, iv, biw_D1 / 4×3w), compound 1 (50 mg / kg, iv, biw_D1 / 4×3w) or compound 2 (10 mg / kg, ip, qd×3w) were given from the day of bleomycin challenge. The mice were killed under anesthesia on the 22nd day.
[0154] The body weight and survival rate of mice were recorded every day. Figure 1A and 1BAs shown, intratracheal bleomycin instillation caused continuous weight loss and death in mice. The average weight of mice dropped from 23.3 ± 0.3 g before bleomycin challenge to 18.8 ± 1.4 g at the end of the study, with a survival rate of 80%. On the other hand, no significant weight loss was observed in mice treated with compound 1 and compound 2, and the survival rates were 100% and 90% at the end of the study.
[0155] Histopathology. The left lungs of mice were fixed with 10% neutral buffered formalin at room temperature for 48 hours, then embedded in paraffin and cut into 4 μm sections. After dewaxing, the lung sections were stained with hematoxylin and eosin (H&E) and Masson's trichrome. Tissue inflammation was evaluated according to the degree of inflammatory cell infiltration using H&E-stained specimens (0 for no visible lesions, 1 for very mild, 2 for mild, 3 for moderate, and 4 for significant). Fibrosis was evaluated according to the eight-layer, modified Ashcroft scale using Masson's trichrome-stained specimens. All assessments were performed in a blinded manner.
[0156] like Figure 2A and 2B As shown, intratracheal instillation of bleomycin caused severe pulmonary fibrosis and inflammation, represented by pathological scores of 6.5±0.1 and 3.7±0.2, respectively. C57BL / 6 mice in the untreated group showed no signs of pulmonary fibrosis and inflammation. Administration of compound 1 and compound 2 significantly reduced the pathological scores of fibrosis and inflammation. 50 mg / kg compound 1 reduced the fibrosis and inflammation scores to 4.1±0.2 and 1.5±0.2, respectively (p<0.0001, compared with the model-solvent group); 10 mg / kg compound 2 reduced the fibrosis and inflammation scores to 5.6±0.2 (p<0.01, compared with the model-solvent group) and 2.2±0.1 (p<0.0001, compared with the model-solvent group), respectively.
[0157] Collagen test. A portion of the right lung was used for collagen determination. The collected lung tissue was added to 6M HCl at a ratio of 1:10 (mg tissue: μL 6M HCl) and incubated at 95°C in a calibrated oven for 20 hours. After cooling back to room temperature, the samples were centrifuged at 13,000g for 10 minutes. The supernatant obtained was appropriately diluted and the collagen content was determined using a total collagen assay kit (QuickZyme, The Netherlands). The data are expressed as micrograms of collagen per right lung.
[0158] like Figure 3As shown, the lungs of mice challenged with bleomycin showed significantly higher collagen deposition than uninfected mice (12.7±1.1 vs 3.0±0.1 μg / right lung, p<0.0001), indicating the formation of fibrosis. Treatment with 50 mg / kg compound 1 significantly reduced the collagen content to 5.6±0.5 g / right lung (p<0.0001, compared with the model-solvent group), which is consistent with the reduction of fibrosis scores.
[0159] Staining for β-galactosidase activity. Half of the right lung was used to prepare cryosections. SA-β-Gal staining was performed using the Senescence β-galactosidase staining kit (Solebo Technology Co., Ltd., Beijing, China) according to the manufacturer's protocol. Images were acquired using a Nikon Eclipse90i microscope, and the number of SA-β-galactosidase-positive cells (i.e., senescent cells) was counted in six random microscopic fields of each sample.
[0160] like Figure 4 As shown, intratracheal instillation of bleomycin caused a significant increase in the number of senescent cells in the lungs of mice (p<0.0001 compared with the untreated group), reaching 10.4±1.2 per field of view. The 50 mg / kg compound 1 and 10 mg / kg compound 2 administration groups significantly reduced the number of senescent cells, which were 6.2±0.6 (p<0.01, compared with the model-solvent group) and 3.9±0.6 (p<0.0001, compared with the model-solvent group) / field of view, respectively.
[0161] Gene expression analysis was performed by quantitative RT-PCR. Total RNA was extracted from the right lung using the RNeasy Mini Kit (Qiagen CA, USA) according to the manufacturer's instructions. After quantification by NanoDrop 2000, the extracted RNA was reverse transcribed using a high-capacity cDNA reverse transcription kit (Applied Biosystems, CA, USA). The RNA was expressed in 4% 4% 2% 2% 1 ... TM qPCR was performed using the 7 Real-Time PCR System (Applied Biosystems, CA, USA). Hprt mRNA was used as a housekeeping gene and quantification was performed using the ΔΔCt method. The transcription levels of SASP-related genes were normalized to Hprt mRNA. All Taqman probes were purchased from Applied Biosystems (CA, USA). Quantitative RT-PCR was also used to determine the transcription levels of BCL-2 and BCL-xL genes, which may contribute to the survival of senescent cells, in which the GAPDH gene was used as a housekeeping gene.
[0162] like Figure 5As shown, the mRNA level of the senescence marker p16 in the lungs of mice challenged with bleomycin was significantly increased compared with that in the untreated group (p<0.0001), indicating that cellular senescence was induced in vivo. Consistent with the reduction of SA-β-Gal positive cells, the mRNA level of the p16 gene was also significantly reduced after compound 1 treatment (p<0.0001, compared with the model-solvent group).
[0163] like Fig. 6A and 6B As shown, the mRNA level of the BCL-xL gene in the lungs of mice stimulated by bleomycin was 1.8 times that of mice in the non-drug group, indicating that the survival of cells in the lungs of mice with idiopathic pulmonary fibrosis depends on BCL-xL, which is consistent with the efficacy of BCL-xL inhibitors, such as compound 1 and compound 2 in this idiopathic pulmonary fibrosis mouse model.
[0164] Figure 7 shows the changes in the transcription levels of SASP-related genes in the lungs of mice with idiopathic pulmonary fibrosis after treatment with compound 1 and compound 2. The mRNA levels of pro-inflammatory (Mcp1, Mmp10 and Il-6) and pro-fibrotic (Pai-1, Il-11 and Tgfb) SASP factors were significantly increased after bleomycin stimulation, but significantly decreased after treatment with compound 1 and compound 2. These results are consistent with the reduction of lung senescence levels (reduced number of SA-β-galactosidase-positive cells and reduced mRNA levels of the p16 gene) and the overall efficacy of fibrosis (reduced collagen content in the lungs and reduced fibrosis scores).
[0165] Immunohistochemistry. The lungs of mice were fixed with 10% neutral buffered formalin solution at room temperature for 48 hours, embedded in paraffin, and sliced to 4 μm. After dewaxing, the lung sections were subjected to IHC staining to detect the expression of BCL-2 and BCL-xL proteins in the lungs of mice. Three representative areas were selected from each slide and then analyzed by ImageJ software to obtain the percentage of positive staining areas.
[0166] like Fig. 8A and 8B As shown, the expression of BCL-2 protein in the lungs of mice challenged with bleomycin was slightly increased compared with that in the untreated group of mice (p>0.05, t-test). On the other hand, the expression level of BCL-xL protein in the lungs of mice challenged with bleomycin was significantly increased compared with that in the untreated group of mice (p<0.05, t-test).
[0167] Example 2. Study of Compound 1 and Compound 2 in a radiation-induced pulmonary fibrosis mouse model.
[0168] Radiation-induced pulmonary fibrosis mouse model. All animal experiments were approved by the Institutional Animal Care and Use Committee of Peking Union Medical College and Institute of Radiation Medicine, Chinese Academy of Medical Sciences. Male C57BL / 6 mice (23-25 g) were randomly divided into the following four groups: (1) untreated group, (2) model + solvent group, (3) compound 1 group, and (4) compound 2 group. The mice in the untreated group were not treated before sacrifice. The other three groups of mice received a single dose of 17 Gy radiation in the right chest. 16 weeks after irradiation, the mice received solvent (model-solvent group, iv, biw_D1 / 4×3w), compound 1 (50 mg / kg, iv, biw_D1 / 4×3w), or compound 2 (10 mg / kg, ip, qd×3w) for 6 weeks.
[0169] like Fig. 9 As shown, all mice in the non-irradiated group survived, and irradiation caused death of animals during the experiment, with a survival rate of 70% at the end of the study. Treatment with compound 1 and compound 2 increased the survival rate of mice to 100% and 90%, respectively, indicating their efficacy in radiation-induced pulmonary fibrosis. Lung tissues were collected and imaged after the mice were sacrificed. Fig.10 As shown, the lungs were significantly enlarged after irradiation, which may be due to inflammation and fibrosis. Treatment with Compound 1 and Compound 2 reduced the lungs almost to normal levels, indicating that inflammation and fibrosis were improved.
[0170] Histopathology. The left lungs of mice were fixed with 10% neutral buffered formalin at room temperature for 48 hours, then embedded in paraffin and cut into 4 μm sections. After dewaxing, the lung sections were stained with hematoxylin and eosin (H&E) and Masson's trichrome. Tissue inflammation was evaluated according to the degree of inflammatory cell infiltration using H&E-stained specimens (0 for no visible lesions, 1 for very mild, 2 for mild, 3 for moderate, and 4 for significant). Fibrosis was evaluated according to the eight-layer, modified Ashcroft scale using Masson's trichrome-stained specimens. All assessments were performed in a blinded manner.
[0171] Staining for β-galactosidase activity. Half of the right lung was used to prepare cryosections. SA-β-Gal staining was performed using the Senescence β-galactosidase staining kit (Solebo Technology Co., Ltd., Beijing, China) according to the manufacturer's protocol. Images were acquired using a Nikon Eclipse90i microscope, and the number of SA-β-galactosidase-positive cells (i.e., senescent cells) was counted in six random microscopic fields of each sample.
[0172] like Fig.11As shown, chest irradiation resulted in a significant increase in the number of senescent cells in the lungs of mice compared to the untreated group (44.0±4.7 vs 8.7±2.1, p<0.0001). Treatment with 50 mg / kg compound 1 and 10 mg / kg compound 2 reduced the number of senescent cells to 42.9±2.5 and 32.4±2.6, respectively. Significant differences were observed in the compound 2 group (p<0.05, vs model-solvent group), suggesting that the clearance of senescent cells may be responsible for the efficacy of radiation-induced lung fibrosis.
[0173] Equivalent
[0174] It should be understood that the present invention may be implemented in other specific forms without departing from the spirit or essential features of the present invention. Therefore, the foregoing embodiments are considered to be illustrative in all aspects, rather than limiting the present invention described herein. Therefore, the scope of the present invention is indicated by the appended claims rather than by the foregoing description, and all changes within the equivalent meaning and scope of the claims are intended to be included therein.
Claims
1. Use of Compound 2 or a pharmaceutically acceptable salt thereof in the preparation of a medicament for treating or preventing radiation-induced pulmonary fibrosis in a subject 2. The method of claim 1, wherein the subject is a mammal.
3. The use according to claim 1, wherein the subject is a human.
4. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration by enteral administration.
5. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for oral administration.
6. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration by parenteral administration.
7. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration by intravenous administration.
8. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration by intratracheal instillation.
9. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration once a day.
10. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration twice a day.
11. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration three or more times per day.
12. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration once a week.
13. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration twice a week.
14. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration three times or more per week.
15. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration for 1 week, 2 weeks or 3 weeks.
16. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration for 3 weeks.
17. The use of claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration twice a week for three weeks.
18. The use according to claim 1, wherein Compound 2 or a pharmaceutically acceptable salt thereof is formulated for administration once daily for 3 weeks.
